Two corporations working for a cure...BD
The deal, worth up to $170m (€115.5m) will see the companies collaborate on the discovery and preclinical development of positive allosteric modulators (PAMs) that target the metabotropic glutamate receptor 4 (mGluR4) for use in the treatment of Parkinson's and other undisclosed indications.
The deal includes an upfront payment of $3m with Addex being eligible for up to $106.5m if certain R&D and regulatory milestones are met. In addition, the company could receive a further $61m if further products are developed as well as undisclosed royalties on sales of any products that reach the market.
0 comments :
Post a Comment